Key result
Colchicine has emerging evidence supporting its efficacy in treating various cardiac conditions including pericarditis, postpericardiotomy syndrome, atrial fibrillation, and coronary artery disease.
Why the study?
Does colchicine improve outcomes in patients with cardiovascular conditions such as pericarditis, atrial fibrillation, and coronary artery disease?
Does colchicine improve outcomes in patients with cardiovascular conditions such as pericarditis, atrial fibrillation, and coronary artery disease?
This review summarizes the rekindled interest and current evidence for utilizing the anti-inflammatory properties of colchicine across multiple cardiovascular conditions.
Answers are grounded in this paper and cite their sources.
Supports colchicine evaluation across CV conditions; leaves open routine adoption pending RCTs.
Colchicine is a well-established drug approved by the Food and Drug Administration (FDA) for the prevention and treatment of gout. It possesses unique anti-inflammatory properties. Interests in the usage of colchicine in cardiovascular medicine have been rekindled recently with several large trials been carried out to investigate its efficacy in treatment of various cardiac conditions including pericarditis, postpericardiotomy syndrome, atrial fibrillation and coronary artery disease. In this review, the basic pharmacological properties of colchicine will be discussed, and the evidences of its benefits for different applications in cardiovascular medicine will be reviewed.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2016) conducted a review in Cardiovascular conditions (pericarditis, postpericardiotomy syndrome, atrial fibrillation, coronary artery disease). Colchicine was evaluated. Colchicine has emerging evidence supporting its efficacy in treating various cardiac conditions including pericarditis, postpericardiotomy syndrome, atrial fibrillation, and coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: